Evan Thomas Hall

12PUBLICATIONS
123CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 09, 2026
Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.

|Aug 27, 2026
Minimal Efficacy of Single-Agent Anti-PD-(L)1 Re-Exposure in Anti-PD-(L)1-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients.

|Sep 19, 2025
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials.

Peter Y Ch'en, Yuzheng Zhang, Daniel S Hippe

|Jul 29, 2025
Sonographic Signatures of Immune Checkpoint Inhibitor-Associated Musculoskeletal Adverse Events.

Hans Vitzthum von Eckstaedt, Kevin Weng, Ingeborg Sacksen

|Jul 07, 2025
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH).

Wenwen Chen, Julia Majovski, Shailender Bhatia

|Jul 25, 2024
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.

Tomoko Akaike, Manisha Thakuria, Ann W Silk

Pageof 2

Frequent Collaborators

5 joint publications

Paul Nghiem

4 joint publications

Tomoko Akaike

4 joint publications

Daniel S Hippe

3 joint publications

Shailender Bhatia